Polymer Drugs in the Clinical Stage Advantages and Prospects /
| Autor Corporativo: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer US : Imprint: Springer,
2003.
|
| Edición: | 1st ed. 2003. |
| Colección: | Advances in Experimental Medicine and Biology,
519 |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/b105364 |
Tabla de Contenidos:
- Challenges in Polymer Therapeutics
- Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS
- PEG-Adenosine Deaminase and PEG-Asparaginase
- Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C
- PEG-Methioninase
- Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate
- HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer
- Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer
- CM-Dextran-Polyalcohol-Camptothecin Conjugate
- Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs
- An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer
- Polymer Conjugates for Imaging
- S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics.